Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DelMar Pharmaceuticals Inc    DMPI

DELMAR PHARMACEUTICALS INC

(DMPI)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI) Files An 8-K Results of Operations and Financial Condition

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 11:40am EDT

DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

DelMar Pharmaceuticals, Inc. (the “Company”) issued a press release on February 12, 2019, disclosing financial information and operating metrics for its three month period ended December 31, 2018, and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

See “Item 2.02 Results of Operation and Financial Condition” above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

DelMar Pharmaceuticals, Inc. Exhibit
EX-99.1 2 f8k021219ex99-1_delmar.htm PRESS RELEASE OF DELMAR PHARMACEUTICALS,…
To view the full exhibit click here

About DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI)

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

The post DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI) Files An 8-K Results of Operations and Financial Condition appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DELMAR PHARMACEUTICALS INC
04/17DELMAR PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change ..
AQ
04/05DELMAR PHARMACEUTICALS : Welcomes Dr. John de Groot, Chairman, ad interim of the..
AQ
04/04DELMAR PHARMACEUTICALS : Receives Approval from MD Anderson Cancer Center's IRB ..
AQ
04/04DELMAR PHARMACEUTICALS : Pharma (DMPI) Gets Approval from Univ. of Texas MDACC`s..
AQ
02/22DELMAR PHARMACEUTICALS : Achieves Halfway Enrollment Point for Phase 2 Clinical ..
AQ
02/12DELMAR PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Re..
AQ
02/11DELMAR PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
02/07DELMAR PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
2018DELMAR PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Conti..
AQ
2018DELMAR PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unreg..
AQ
More news
Financials ($)
Chart DELMAR PHARMACEUTICALS INC
Duration : Period :
DelMar Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DELMAR PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Saiid Zarrabian President, CEO & Independent Director
Robert E. Hoffman Chairman
Scott Praill CFO & Principal Accounting Officer
Dennis M. Brown Chief Scientific Officer
John K. Bell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DELMAR PHARMACEUTICALS INC7.11%9
CK HUTCHISON HOLDINGS LTD10.03%40 714
INVESTOR AB16.80%36 068
KINNEVIK20.50%7 630
REMGRO LIMITED2.88%7 419
KOC HOLDING AS--.--%7 376